scholarly journals 1040O Phase II trial of ipilimumab, nivolumab and tocilizumab for unresectable metastatic melanoma

2021 ◽  
Vol 32 ◽  
pp. S869
Author(s):  
J.S. Weber ◽  
T. Muramatsu ◽  
O. Hamid ◽  
J. Mehnert ◽  
F.S. Hodi ◽  
...  
Keyword(s):  
Metastatic Melanoma ◽  
Phase Ii ◽  
Phase Ii Trial

scholarly journals A Phase II Trial of Sorafenib in Metastatic Melanoma with Tissue Correlates

PLoS ONE ◽  
2010 ◽  
Vol 5 (12) ◽  
pp. e15588 ◽  
Author(s):  
Patrick A. Ott ◽  
Anne Hamilton ◽  
Christina Min ◽  
Sara Safarzadeh-Amiri ◽  
Lauren Goldberg ◽  
...  
Keyword(s):  
Metastatic Melanoma ◽  
Phase Ii ◽  
Phase Ii Trial

A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma

2010 ◽  
Vol 30 (1) ◽  
pp. 341-349 ◽  
Author(s):  
Simon Pacey ◽  
Martin Gore ◽  
David Chao ◽  
Udai Banerji ◽  
James Larkin ◽  
...  
Keyword(s):  
Metastatic Melanoma ◽  
Phase Ii ◽  
Phase Ii Trial

scholarly journals Phase II trial of biochemotherapy with interferon α, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a Southwest Oncology Group trial

1999 ◽  
Vol 125 (5) ◽  
pp. 292-296 ◽  
Author(s):  
Kim A. Margolin ◽  
P. Y. Liu ◽  
Joseph M. Unger ◽  
William S. Fletcher ◽  
Lawrence E. Flaherty ◽  
...  
Keyword(s):  
Metastatic Melanoma ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Interferon Α ◽  
Oncology Group ◽  
Southwest Oncology Group ◽  
Group Trial

Phase II trial of imatinib mesylate (STI-571) in metastatic melanoma (MM)

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 7528-7528 ◽  
Author(s):  
O. Eton ◽  
L. Billings ◽  
K. Kim ◽  
V. Prieto ◽  
D. Davis ◽  
...  
Keyword(s):  
Metastatic Melanoma ◽  
Imatinib Mesylate ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Sti 571

CCI-779 in metastatic melanoma: A phase II trial of the California Cancer Consortium

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 7523-7523 ◽  
Author(s):  
K. A. Margolin ◽  
J. Longmate ◽  
T. Baratta ◽  
T. Synold ◽  
J. Weber ◽  
...  
Keyword(s):  
Metastatic Melanoma ◽  
Phase Ii ◽  
Phase Ii Trial

CPG 7909, a TLR9 agonist immunomodulator in metastatic melanoma: A randomized phase II trial comparing two doses and in combination with DTIC

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 7526-7526 ◽  
Author(s):  
S. Wagner ◽  
J. Weber ◽  
B. Redman ◽  
T. Schmalbach ◽  
D. Bright ◽  
...  
Keyword(s):  
Metastatic Melanoma ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Tlr9 Agonist ◽  
Randomized Phase Ii

Final results of phase II trial of pegylated arginine deiminase (ADI-PEG20) in metastatic melanoma (MM).

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 8528-8528 ◽  
Author(s):  
L. G. Feun ◽  
M. You ◽  
C. Wu ◽  
M. Wangpaichitr ◽  
M. T. Kuo ◽  
...  
Keyword(s):  
Metastatic Melanoma ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Arginine Deiminase
Sign in / Sign up

Export Citation Format

Share Document